UAE Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion Sys
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUAE Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion Sys
| Forecast Period | 2024-2028 |
| Market Size (2023) | 0.20 billion |
| CAGR (2024-2029) | 2.21% |
| Fastest Growing Segment | Type II Diabetes Segment |
| Largest Market | Abu Dhabi |
Market Overview
UAE Human Insulin Market has valued at USD 0.20 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 2.21% through 2029.
Ongoing research and development in the field of diabetes and insulin therapies contribute to the introduction of innovative and more effective insulin products. The availability of advanced and improved insulin formulations can drive market growth. Advances in insulin delivery systems, such as insulin pens, pumps, and smart devices, enhance patient convenience and adherence. The adoption of these technologies can stimulate market growth.
Key Market Drivers
Advancements in Insulin Therapies
Analog insulins are designed to mimic the body's natural insulin production more closely than traditional human insulins. Rapid-acting analogs, such as insulin lispro, aspart, and glulisine, offer quicker onset and shorter duration of action, allowing for more precise control over postprandial glucose levels. Long-acting insulin analogs, including insulin glargine and insulin detemir, provide a more stable and prolonged release of insulin, offering a basal level of coverage and reducing the risk of hypoglycemia compared to traditional long-acting insulins. Ultra-rapid insulins, like insulin lispro U100 and U200, are engineered to have an even faster onset of action and a shorter duration than traditional rapid-acting insulins. These can be particularly useful for post-meal glucose control. Inhaled insulin formulations, such as Afrezza, offer an alternative to injectable insulins. Administered through an inhaler, inhaled insulin provides a rapid onset of action and may be preferred by some patients who are averse to injections.
Smart insulin pens are equipped with Bluetooth or other connectivity features that allow them to sync with mobile apps or glucose monitoring devices. These pens can track insulin doses, provide reminders, and offer data insights to both patients and healthcare providers. Closed-loop systems combine continuous glucose monitoring (CGM) with an insulin pump to automatically adjust insulin delivery based on real-time glucose levels. This technology aims to mimic the function of the pancreas more closely, providing better glucose control. Biosimilar insulins are biologic products that are highly similar to existing insulin therapies. These alternatives offer potential cost savings and increased access to insulin treatments.
Insulin pump technologies have seen advancements, including smaller and more discreet designs, improved infusion sets, and features such as predictive low glucose suspension (PLGS) to prevent hypoglycemia. Some research is focused on the development of dual-hormone artificial pancreas systems that deliver both insulin and glucagon. This approach aims to provide more precise control over blood glucose levels. Ongoing research explores novel formulations, such as oral insulin and stabilized injectable formulations, to improve the absorption and stability of insulin, potentially offering additional options for patients. This factor will help in the development of the
Growing Aging Population
The risk of developing diabetes tends to increase with age. As individuals age, their bodies may become less efficient in producing or utilizing insulin, leading to a higher prevalence of diabetes, particularly type 2 diabetes. This, in turn, drives the demand for insulin as a therapeutic option. The aging population is often associated with a higher incidence of diabetes. Factors such as sedentary lifestyles, poor dietary habits, and genetic predispositions can contribute to the development of diabetes in older individuals, necessitating insulin therapy for proper glycemic control. Type 2 diabetes, which is more common in older adults, often requires insulin therapy as the disease progresses. The aging population, therefore, contributes to the increasing demand for human insulin, especially as a part of the treatment regimen for individuals with type 2 diabetes. With advancements in healthcare and improved living conditions, people are living longer. The extended life expectancy increases the likelihood of chronic health conditions, including diabetes, necessitating ongoing management and treatment, often involving insulin.
Aging is associated with changes in insulin sensitivity, insulin resistance, and pancreatic function. These physiological changes can result in a higher prevalence of diabetes among older adults, leading to an increased need for insulin therapy. Older adults may experience multiple comorbidities and complications related to diabetes. Insulin therapy becomes crucial in managing blood glucose levels effectively, preventing complications, and improving overall health outcomes. Healthcare systems often focus on public health strategies to address the needs of aging populations. This may include diabetes management programs that highlight the importance of insulin therapy in maintaining health and quality of life for older individuals. Advancements in geriatric medicine and healthcare practices for older adults may contribute to better diabetes management, including the appropriate use of insulin therapy tailored to the needs of elderly patients. This factor will pace up the demand of the
Lifestyle Changes and Urbanization
Urbanization often brings about changes in lifestyle, with individuals adopting more sedentary behaviors. Lack of physical activity is a key risk factor for the development of type 2 diabetes, prompting an increased demand for insulin as a treatment option. Urbanization is frequently associated with the availability of processed and high-calorie foods, leading to unhealthy dietary habits. Poor nutrition and overconsumption of sugary and fatty foods contribute to the rising prevalence of diabetes, necessitating insulin therapy for glycemic control. Urbanization is often linked to an increase in obesity rates. Obesity is a major risk factor for insulin resistance and the development of type 2 diabetes. The growing prevalence of obesity worldwide has resulted in a higher demand for insulin among individuals with diabetes. Urban living is often associated with increased stress levels due to factors such as fast-paced work environments, long commutes, and other stressors. Chronic stress can contribute to insulin resistance, making insulin therapy necessary for managing diabetes.
Studies have indicated that the risk of diabetes is often higher in urban areas compared to rural settings. Factors such as lifestyle changes, dietary patterns, and reduced physical activity in urban environments contribute to the higher demand for insulin. Urbanization is accompanied by improved access to healthcare facilities, making it easier for individuals to seek medical attention and receive a diabetes diagnosis. Increased access to healthcare contributes to early detection of diabetes and a subsequent rise in insulin therapy prescriptions. Urban environments are often hubs for health awareness campaigns and educational programs. As people become more informed about the risks of diabetes and the importance of early intervention, there is a greater likelihood of seeking medical advice and initiating insulin therapy when needed.
Urban lifestyles are characterized by a reliance on processed and convenience foods, which are often high in refined sugars and carbohydrates. This dietary shift contributes to insulin resistance and the need for insulin therapy among individuals with diabetes. Some regions experiencing rapid urbanization, particularly in developing countries, face a diabetes epidemic. The transition from traditional diets to more Westernized, urban diets is a major contributing factor, leading to an increased demand for insulin. Urban areas typically have more advanced healthcare infrastructure, including hospitals, clinics, and pharmacies. This infrastructure supports the diagnosis, treatment, and management of diabetes, contributing to the overall demand for insulin. This factor will accelerate the demand of the UAE Human Insulin Market.
Download Sample Report
Key Market Challenges
Market Access and Pricing
The regulatory framework in the UAE, including pricing regulations and market access policies, can impact the entry of insulin products into the market. Stringent regulatory requirements may create barriers for some manufacturers, affecting the availability of diverse insulin options. The pricing of insulin products is influenced by various factors, including production costs, research and development expenses, and market competition. Manufacturers may face challenges in setting prices that are both competitive and reflective of the value provided by their products. Access to insulin is often dependent on health insurance coverage. Challenges may arise if insurance coverage is limited or if there are restrictions on reimbursement for certain insulin formulations. This can affect affordability for patients and influence market access. The cost of insulin is a critical factor that directly impacts patients' ability to access and adhere to their prescribed treatments. Affordability challenges can lead to decreased compliance and negatively affect health outcomes. Importing insulin products and distributing them across the UAE can incur additional costs, including customs duties, transportation, and storage expenses. These factors can contribute to pricing challenges and affect market access.
Patient Adherence
Some individuals may perceive insulin therapy as a last resort or associate it with the progression of their disease. Fear of injections, stigma surrounding insulin use, or concerns about social judgment can hinder patient acceptance and adherence. Fear or anxiety related to needles and injections is a common issue that can affect patient adherence to insulin therapy. This phobia may lead to avoidance or irregular administration of insulin doses. Insulin therapy often involves complex dosing regimens, including multiple injections per day or a combination of different insulin types. The complexity of these regimens can overwhelm some patients, leading to errors or non-adherence. Insufficient education and awareness about diabetes and the importance of insulin therapy can contribute to poor adherence. Patients need a clear understanding of their condition, the rationale behind insulin therapy, and proper administration techniques. The cost of insulin and associated supplies can be a barrier to adherence, especially if patients face financial constraints or have limited access to health insurance coverage. Affordability issues may lead to rationing of insulin or discontinuation of therapy. Cultural factors and beliefs can influence health-related behaviors. In some cases, cultural attitudes toward illness, treatment, or traditional remedies may impact a patient's willingness to adhere to prescribed insulin therapy. Patients with limited health literacy may struggle to understand healthcare information, including instructions for insulin therapy. This can hinder their ability to manage their condition effectively.
Key Market Trends
Development of Biosimilar Insulins
Biosimilar insulins have the potential to offer cost savings compared to their reference products. This can enhance accessibility to insulin therapy, especially in regions where affordability is a critical factor for patients. The development and approval of biosimilar insulins provides healthcare professionals and patients with a broader range of treatment options. This diversification can be beneficial in tailoring diabetes management to individual patients’ needs. The introduction of biosimilar insulins fosters competition within the market. Increased competition may lead to competitive pricing and improved access to insulin therapies, benefiting patients and healthcare systems. Regulatory agencies, including those in the UAE, have been providing frameworks for the approval and commercialization of biosimilar products. Regulatory support facilitates the entry of biosimilar insulins into the market, contributing to their adoption. As biosimilar insulins gain acceptance and successful track records in various international markets, their adoption becomes more likely in other regions, including the UAE.
Segmental Insights
Indication Insights
In 2023, the UAE Human Insulin Market largest share was held by Type Il Diabetes segment and is predicted to continue expanding over the coming years.
Type Insights
In 2023, the UAE Human Insulin Market largest share was held by pre-mixed segment and is predicted to continue expanding over the coming years.
Products Insights
Insulin Pens
Download Sample Report
Regional Insights
The Abu Dhabi region dominates the UAE Human Insulin Market in 2023. Abu Dhabi is the capital and economic hub of the United Arab Emirates (UAE). The region's economic strength and development can attract healthcare investments and foster a robust pharmaceutical industry, including the insulin market. The presence of advanced healthcare infrastructure, medical facilities, and research institutions in Abu Dhabi may contribute to the dominance in the insulin market. Access to state-of-the-art medical facilities often attracts pharmaceutical companies and supports market growth. The Abu Dhabi government has implemented specific initiatives or policies to promote healthcare, diabetes management, or the pharmaceutical sector, this could positively impact the human insulin market in the region. The population density and demographic composition of Abu Dhabi may play a role. If there is a higher prevalence of diabetes or a larger population in need of insulin therapy in Abu Dhabi compared to other regions, it could lead to market dominance.
Recent Developments
- In April 2022, NeoBiocon, acollaboration between Biocon Ltd, a leading biopharmaceutical company in Asia,and Dr. B.R. Shetty, Chairman of Neopharma in the UAE, has announced astrategic partnership with Novartis Middle East FZE. The collaboration aims tomarket Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in theUnited Arab Emirates (UAE). This venture is set to enhance NeoBiocon's productportfolio in the metabolics segment, offering significant benefits toindividuals with diabetes in the UAE. Vildagliptin, an oral anti-diabeticagent, provides consistent and robust blood sugar control for patients withtype 2 diabetes. As a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, itis known for its weight-neutral effects and a low risk of hypoglycemia. NeoBioconhas secured approvals from the Ministry of Health-UAE for the marketing ofJalra and Jalra-M in the country, with the launch scheduled for January 2016.
Key Market Players
- Novo Nordisk Pharma Gulf FZ-LLC
- Sanofi UAE
- Baxter International UAE
- B. Braun Medical Gulf FZ – LLC
- Eli Lilly and Company UAE
- Becton Dickinson And Company UAE
- Gulf Pharmaceutical Industries P.S.C. (Julphar)
| By Indication | By Route of Administration | By Type | By Onset Time | By Products | By Region |
| Type I Diabetes Type Il Diabetes | Subcutaneous Nasal Intravenous Transdermal Oral Others | Basal Bolus Pre-mixed Biosimilar Traditional | Rapid Acting Short-Acting Intermediate Acting Long Acting Ultra-long Acting Pre-Mixed Inhaled | Insulin Pens Insulin Pumps Infusion System Injection | Dubai Abu Dhabi Sharjah Rest of UAE |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy